









市場行情
/
股票
/
nasdaq-axsm
/

Axsome Therapeutics Inc

AXSM

152.650USD

+5.650+3.84%

收盤 12/19, 16:00（美東）報價延遲15分鐘

7.68B總市值

虧損本益比TTM



Axsome Therapeutics Inc

152.650

+5.650+3.84%

概覽公司財務分析

概覽

公司

財務

分析

關於 Axsome Therapeutics Inc 公司

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.

Axsome Therapeutics Inc簡介



公司代碼AXSM

公司名稱Axsome Therapeutics Inc

上市日期Nov 19, 2015

CEOTabuteau (Herriot)

員工數量683

證券類型Ordinary Share

年結日Nov 19

公司地址One World Trade Center, 29Th Floor

城市NEW YORK

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編10007

電話12123323241

網址https://www.axsome.com/

公司代碼AXSM

上市日期Nov 19, 2015

CEOTabuteau (Herriot)

Axsome Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Roger A. Jeffs, Ph.D.

Independent Director

57.51K

-18.97%

Mr. Nick Pizzie, CPA

Chief Financial Officer

42.67K

-1.00%

Mr. Mark E. Saad

Independent Director

10.30K

Dr. Herriot Tabuteau, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

7.23K

Mr. Hunter Murdock

General Counsel

Mr. Mark L. Jacobson

Chief Operating Officer

-100.00%

Dr. Susan M. (Sue) Mahony, Ph.D.

Independent Director

Dr. Mark Coleman, M.D.

Lead Independent Director

Mr. Ari Maizel

Chief Commercial Officer

名稱

名稱/職務

職務

持股

持股變動

Dr. Roger A. Jeffs, Ph.D.

Independent Director

57.51K

-18.97%

Mr. Nick Pizzie, CPA

Chief Financial Officer

42.67K

-1.00%

Mr. Mark E. Saad

Independent Director

10.30K

Dr. Herriot Tabuteau, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

7.23K

Mr. Hunter Murdock

General Counsel

Mr. Mark L. Jacobson

Chief Operating Officer

-100.00%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2023

FY2023Q4

FY2023Q3

業務USD

名稱

營收

佔比

Auvelitv

119.64M

80.32%

Sunosi

28.91M

19.41%

Sunosi royality revenue

1.08M

0.73%

Sunosi License revenue

410.00K

0.28%

地區USD

名稱

營收

佔比

United States

146.45M

98.31%

Outside of the United States

2.51M

1.69%

業務

地區

業務USD

名稱

營收

佔比

Auvelitv

119.64M

80.32%

Sunosi

28.91M

19.41%

Sunosi royality revenue

1.08M

0.73%

Sunosi License revenue

410.00K

0.28%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Antecip Capital, L.L.C.

14.57%

The Vanguard Group, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

6.16%

Wellington Management Company, LLP

2.65%

RTW Investments L.P.

2.22%

其他

66.13%

持股股東

佔比

Antecip Capital, L.L.C.

14.57%

The Vanguard Group, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

6.16%

Wellington Management Company, LLP

2.65%

RTW Investments L.P.

2.22%

其他

66.13%

股東類型

持股股東

佔比

Investment Advisor

36.04%

Investment Advisor/Hedge Fund

21.86%

Corporation

14.57%

Hedge Fund

11.48%

Research Firm

2.23%

Private Equity

1.35%

Individual Investor

1.13%

Pension Fund

1.11%

Sovereign Wealth Fund

0.93%

其他

9.30%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

643

38.50M

85.28%

+81.77K

2025Q3

657

38.45M

87.16%

-264.98K

2025Q2

636

38.74M

85.21%

+673.17K

2025Q1

604

38.08M

85.89%

-4.20M

2024Q4

561

37.78M

89.40%

-1.53M

2024Q3

529

39.25M

94.83%

-2.09M

2024Q2

515

41.51M

92.29%

+1.90M

2024Q1

502

39.61M

93.44%

-4.74M

2023Q4

476

39.34M

91.45%

+441.54K

2023Q3

467

38.94M

87.84%

+1.52M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Antecip Capital, L.L.C.

7.34M

14.72%

Apr 14, 2025

The Vanguard Group, Inc.

3.94M

7.89%

+67.64K

+1.75%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.14M

6.3%

+173.97K

+5.86%

Jun 30, 2025

Wellington Management Company, LLP

725.04K

1.45%

+21.77K

+3.09%

Jun 30, 2025

RTW Investments L.P.

1.52M

3.04%

-1.41M

-48.10%

Jun 30, 2025

Nomura Investment Management Business Trust

1.14M

2.28%

+161.49K

+16.54%

Jun 30, 2025

Geode Capital Management, L.L.C.

989.45K

1.98%

+54.60K

+5.84%

Jun 30, 2025

T. Rowe Price Associates, Inc.

575.94K

1.15%

+546.97K

+1888.32%

Jun 30, 2025

Invesco Advisers, Inc.

528.53K

1.06%

-217.30K

-29.14%

Jun 30, 2025

State Street Investment Management (US)

958.50K

1.92%

+52.48K

+5.79%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

4.69%

ALPS Medical Breakthroughs ETF

2.85%

State Street SPDR S&P Pharmaceuticals ETF

2.84%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.73%

iShares U.S. Pharmaceuticals ETF

2.09%

Virtus LifeSci Biotech Products ETF

2.03%

ProShares Ultra Nasdaq Biotechnology

0.92%

iShares Health Innovation Active ETF

0.89%

JPMorgan Healthcare Leaders ETF

0.8%

VanEck Pharmaceutical ETF

0.75%

iShares Neuroscience and Healthcare ETF

佔比4.69%

ALPS Medical Breakthroughs ETF

佔比2.85%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.84%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比2.73%

iShares U.S. Pharmaceuticals ETF

佔比2.09%

Virtus LifeSci Biotech Products ETF

佔比2.03%

ProShares Ultra Nasdaq Biotechnology

佔比0.92%

iShares Health Innovation Active ETF

佔比0.89%

JPMorgan Healthcare Leaders ETF

佔比0.8%

VanEck Pharmaceutical ETF

佔比0.75%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Axsome Therapeutics Inc的前五大股東是誰？



Axsome Therapeutics Inc的前五大股東如下：
Antecip Capital, L.L.C.
持有股份：7.34M
佔總股份比例：14.72%。
The Vanguard Group, Inc.
持有股份：3.94M
佔總股份比例：7.89%。
BlackRock Institutional Trust Company, N.A.
持有股份：3.14M
佔總股份比例：6.30%。
Wellington Management Company, LLP
持有股份：725.04K
佔總股份比例：1.45%。
RTW Investments L.P.
持有股份：1.52M
佔總股份比例：3.04%。